Thomas Cartwright

Dr. Thomas Cartwright

Associate Professor of Medicine University of Central Florida School of Medicine

Research Focus & Metrics

Academic Career Length

22Years (2005-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 September 2012 in Clinical Colorectal Cancer
Verified
Journal Article
Closed access
TCThomas Cartwright
Thomas Cartwright

1 October 2008 in Cancer Control
Verified
Journal Article
Open access
PDF file
TCThomas Cartwright
Thomas Cartwright
DRDonald A. Richards
Donald A. Richards
KBKristi A. Boehm
Kristi A. Boehm
Pancreatic cancer is the fourth leading cause of cancer deaths in the United States. In 2008, approximately 37,680 people will be diagnosed with pancreatic cancer and 34,290 will die of this disease. The authors reviewed the literature on treatment of pancreatic cancer with an emphasis on studies conducted in the US Oncology Research (USOR) Network. Although much research has been conducted to develop improved systemic therapies of pancreatic cancer, gemcitabine as a single agent remains the current standard of care. Combinations with other chemotherapeutic drugs or biological agents have resulted in limited improvement. Despite aggressive efforts to improve treatment for patients with pancreatic cancer, limited progress has been made. It is hoped that new studies being planned and conducted will improve outcomes for patients with this disease.

28 January 2017 in Pharmaceuticals
Verified
Journal Article
Open access
PDF file
BMBradley J. Monk
Bradley J. Monk
PLPhilip E. Lammers
Philip E. Lammers
TCThomas Cartwright
Thomas Cartwright
IJIra Jacobs
Ira Jacobs
Access to bevacizumab, an important component of oncology treatment regimens, may be limited. This survey of oncologists in the US (n = 150), Europe (n = 230), and emerging markets (EM: Brazil, Mexico, and Turkey; n = 130) examined use of and barriers to accessing bevacizumab as treatment of advanced solid tumors. We also assessed the likelihood that physicians would prescribe a bevacizumab biosimilar, if available. Bevacizumab was frequently used as early-line therapy in metastatic colorectal cancer, metastatic non-squamous non–small-cell lung cancer, and metastatic ovarian cancer (all markets), and as a second-line therapy in glioblastoma multiforme (US, EM). A greater percentage of EM-based physicians cited access-related issues as a barrier to prescribing bevacizumab versus US and EU physicians. Lack of reimbursement and high out-of-pocket costs were cited as predominant barriers to prescribing and common reasons for reducing the number of planned cycles. Overall, ~50% of physicians reported they “definitely” or “probably” would prescribe a bevacizumab biosimilar, if available. Efficacy and safety data in specific tumor types and lower cost were factors cited that would increase likelihood to prescribe a bevacizumab biosimilar. A lower cost bevacizumab biosimilar could address the unmet needs of patients and physicians worldwide, and may have the greatest impact on patient outcomes in EM.

26 June 2018 in Drugs - Real World Outcomes
Verified
Journal Article
Open access
PDF file
TCThomas Cartwright
Thomas Cartwright
MPMonika Parisi
Monika Parisi
JEJanet L. Espirito
Janet L. Espirito
TWThomas W. Wilson
Thomas W. Wilson
CPCorey Pelletier
Corey Pelletier
HMHani Babiker, MD
Hani Babiker, MD
Background The combination chemotherapy regimens of nab-paclitaxel plus gemcitabine (nab-p + G) and FOLFIRINOX (FFX) have each demonstrated improved survival compared with gemcitabine monotherapy in clinical trials for metastatic pancreatic cancer; however, limited comparative data exist. Objective The objective of this study was to compare patient characteristics and clinical outcomes including time to treatment failure and overall survival in patients with metastatic pancreatic cancer receiving first-line chemotherapy in the community. Methods We conducted a retrospective, multi-site, observational cohort study of patients with metastatic pancreatic cancer receiving first-line nab-p + G, FFX, or gemcitabine monotherapy between April 2013 and October 2015, using data from the iKnowMed electronic health record database. Patients on clinical trials or with other cancer diagnoses were excluded. Time to treatment failure and overall survival were assessed by Kaplan–Meier methods. Results Four hundred and eighty-six patients met selection criteria, 255 nab-p + G, 159 FFX, and 72 gemcitabine patients. Median age was 61, 68, and 73 years for FFX, nab-p + G, and gemcitabine patients, respectively (p < 0.01 for nab-p + G vs. FFX). Eastern Cooperative Oncology Group performance status of 0–1 was 91% for FFX, 77% for nab-p + G, and 68% for gemcitabine patients (p < 0.01 for nab-p + G vs. FFX). For the nab-p + G vs. FFX cohorts, respectively, time to treatment failure was 3.7 vs. 4.3 months (log-rank p = 0.25); and OS was 9.8 vs. 11.4 months (log-rank p = 0.38). Among patients with Eastern Cooperative Oncology Group performance status 0–1, time to treatment failure was 4.2 vs. 4.3 months (log-rank p = 0.47); and overall survival was 12.1 vs 11.4 months (log-rank p = 0.68). Conclusions The nab-p + G patients were older and had worse performance status than FFX patients. Time to treatment failure and overall survival were not observed to be significantly different in first-line nab-p + G and FFX patients. Results were similar after stratifying by performance status.

1 December 2012 in Clinical Colorectal Cancer
Verified
Journal Article
Closed access
TCThomas Cartwright
Thomas Cartwright
YYYeun Mi Yim
Yeun Mi Yim
EYElaine Yu
Elaine Yu
HCHsingwen Chung
Hsingwen Chung
MHMelissa Halm
Melissa Halm
MFMichael Forsyth
Michael Forsyth

1 May 2005 in Clinical Colorectal Cancer
Verified
Journal Article
Closed access
TCThomas Cartwright
Thomas Cartwright
TLTimothy Lopez
Timothy Lopez
SVSvetislava J. Vukelja
Svetislava J. Vukelja
CECarlos Encarnacion
Carlos Encarnacion
KBKristi A. Boehm
Kristi A. Boehm
LALina Asmar
Lina Asmar